Swenson Pharmacy Advisors (SPA)

📊 𝐀𝐧𝐚𝐥𝐲𝐳𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐬 𝐀𝐜𝐫𝐨𝐬𝐬 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐒𝐀 📊 A comprehensive study published in 𝑻𝑯𝑬 𝑳𝑨𝑵𝑪𝑬𝑻 𝑷𝒖𝒃𝒍𝒊𝒄 𝑯𝒆𝒂𝒍𝒕𝒉 explores the variations in cancer rates among adults born between 1920 and 1990 in the USA. This in-depth analysis highlights significant shifts in cancer incidence and mortality, providing valuable insights into the evolving landscape of cancer across different generations. 🔸𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬: 🔷 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐈𝐧𝐜𝐢𝐝𝐞𝐧𝐜𝐞 𝐢𝐧 𝐘𝐨𝐮𝐧𝐠𝐞𝐫 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬: The study reveals a rise in cancer incidence rates for 17 out of 34 cancer types in successively younger birth cohorts. This trend is particularly noticeable in cancers such as small intestine, thyroid, kidney, and pancreas. 🔷 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐎𝐛𝐞𝐬𝐢𝐭𝐲-𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫𝐬: Obesity-related cancers, including colorectal, uterine corpus, and pancreatic cancers, show a marked increase in younger generations, emphasizing the role of early-life exposures and lifestyle factors. 🔷 𝐌𝐨𝐫𝐭𝐚𝐥𝐢𝐭𝐲 𝐓𝐫𝐞𝐧𝐝𝐬: While incidence rates have increased, mortality rates for several cancers have either stabilized or declined, likely due to advancements in early detection and treatment. 🔷 𝐒𝐨𝐜𝐢𝐨𝐞𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐈𝐦𝐩𝐚𝐜𝐭: The study also highlights disparities in cancer rates based on socioeconomic status, indicating that lower-income populations experience higher incidence and mortality rates, underscoring the need for targeted public health interventions. 🔸 𝐑𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧: The study emphasizes the importance of early detection, lifestyle modifications, and targeted interventions to mitigate the rising cancer incidence among younger populations. Strategies include promoting healthy diets, increasing physical activity, and reducing exposure to known carcinogens. 🔗 𝐖𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐘𝐨𝐮𝐓𝐮𝐛𝐞 𝐜𝐥𝐢𝐩: https://lnkd.in/gskX5_3M 🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐮𝐝𝐲: https://lnkd.in/gF-MdeTe #CancerResearch #PublicHealth #Epidemiology #Healthcare #CancerPrevention ♻️ 𝐑𝐞𝐩𝐨𝐬𝐭 𝐭𝐡𝐢𝐬 𝐢𝐟 𝐲𝐨𝐮 𝐟𝐨𝐮𝐧𝐝 𝐢𝐭 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐟𝐮𝐥. 𝐒𝐡𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐚𝐧𝐲𝐨𝐧𝐞 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡! ♻️ 🌐 𝐒𝐰𝐞𝐧𝐬𝐨𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐬 (𝐒𝐏𝐀) 𝐖𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/gWFbVAjz 

🚀 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐀𝐖𝐒 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 🚀 Artificial intelligence and machine learning are revolutionizing various sectors, and healthcare is no exception. With $4.5 trillion spent in 2022, tech giants like Amazon Web Services (AWS) are at the forefront of this transformation. Leading the charge is Dr. Angela Shippy MD, a medical doctor turned executive at AWS. 🎯 𝐁𝐫𝐢𝐝𝐠𝐢𝐧𝐠 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: Dr. Shippy's unique background allows her to bridge the gap between day-to-day healthcare operations and innovative technologies. She collaborates with over 700 healthcare leaders across the U.S. to integrate AWS-backed technology, such as AI-powered rooms and virtual intensive care services, which aim to alleviate administrative burdens and enhance patient care. 💡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬: 🔹 𝐄𝐜𝐡𝐨 𝐃𝐨𝐭: Patients can use voice commands for simple tasks like controlling lights, reducing the workload on staff. 🔹 𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐈𝐧𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐂𝐚𝐫𝐞 𝐔𝐧𝐢𝐭: Allows nurses to monitor more patients efficiently, improving patient outcomes and reducing burnout. 🔹 𝟑𝐃 𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐑𝐞𝐚𝐥𝐢𝐭𝐲: Tools like 3D virtual hearts for patient education and training. 📉 𝐂𝐨𝐬𝐭-𝐄𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬 𝐚𝐧𝐝 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲: Cloud migration is a critical step for many hospitals, with organizations reducing IT costs by 60% through AWS. This digital transformation is projected to grow, with the healthcare tech market expected to reach over $115 billion by 2030. 🌍 𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐔𝐧𝐝𝐞𝐫𝐫𝐞𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐢𝐞𝐬: Dr. Shippy is passionate about raising the profile of women and minorities in tech and healthcare. She emphasizes the importance of inclusive decision-making and strives to ensure that everyone has access to quality healthcare. 🤝 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: Dr. Shippy’s work at AWS exemplifies how technology can address labor shortages, enhance patient care, and improve operational efficiency. By leveraging AI and cloud technology, healthcare providers can focus more on patient care, leading to better health outcomes. 🔗 𝐖𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐯𝐢𝐝𝐞𝐨: https://lnkd.in/eqnxHYY3 #HealthcareInnovation #AIinHealthcare #AWS #CloudComputing #PatientCare ♻️ 𝐑𝐞𝐩𝐨𝐬𝐭 𝐭𝐡𝐢𝐬 𝐢𝐟 𝐲𝐨𝐮 𝐟𝐨𝐮𝐧𝐝 𝐢𝐭 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐟𝐮𝐥. 𝐒𝐡𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐚𝐧𝐲𝐨𝐧𝐞 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲! ♻️ 🌐 𝐒𝐰𝐞𝐧𝐬𝐨𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐬 (𝐒𝐏𝐀) 𝐖𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/gWFbVAjz

CMS has released the prices of the first 10 drugs negotiated by Medicare under the Inflation Reduction Act. In all cases, the discounts are even higher than most payers expected (Formulary Insights primary market research). Payer strategies are no doubt being refined today, significantly impacting the manufacturers of these drugs as well as their competitors. We can help you assess payers' next moves. #marketaccess #biopharma #drugprices The table below provided by Endpoints News.

💊 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐨𝐥𝐞 𝐨𝐟 𝐏𝐁𝐌𝐬 𝐢𝐧 𝐏𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭𝐬: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐇𝐨𝐮𝐬𝐞 𝐎𝐯𝐞𝐫𝐬𝐢𝐠𝐡𝐭 𝐂𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐞 💊 The House Oversight Committee has recently released an in-depth report exploring the role of Pharmacy Benefit Managers (PBMs) in the prescription drug market. This comprehensive analysis sheds light on the intricate operations of PBMs and their impact on drug pricing and access. 🔸 𝐇𝐨𝐮𝐬𝐞 𝐎𝐯𝐞𝐫𝐬𝐢𝐠𝐡𝐭 𝐂𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐞: The House Oversight and Accountability Committee, a key investigative body within the U.S. Congress, is responsible for reviewing and investigating the operations of various sectors within the U.S. government and industry. This report is part of their ongoing efforts to provide transparency and understanding of critical areas in healthcare. 🔸 𝐈𝐧-𝐃𝐞𝐩𝐭𝐡 𝐄𝐱𝐚𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧: The report provides a detailed examination of how PBMs operate within the pharmaceutical supply chain, discussing their roles in drug price negotiations, formulary management, and interactions with pharmacies and manufacturers. It offers insights into the complexities and functions of PBMs in the broader context of prescription drug management. 🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐩𝐨𝐫𝐭 𝐡𝐞𝐫𝐞: https://lnkd.in/epiF-8M5 #Healthcare #PBM #Pharmacy #PrescriptionDrugs

🤖 𝐌𝐚𝐜𝐡𝐢𝐧𝐞 𝐋𝐞𝐚𝐫𝐧𝐢𝐧𝐠 𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐞𝐬 𝐏𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐒𝐮𝐛𝐭𝐲𝐩𝐞𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐓𝐮𝐦𝐨𝐫 𝐌𝐢𝐜𝐫𝐨𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 𝐨𝐟 𝐍𝐒𝐂𝐋𝐂 🤖 A recent study titled "𝑴𝒂𝒄𝒉𝒊𝒏𝒆 𝒍𝒆𝒂𝒓𝒏𝒊𝒏𝒈 𝒊𝒅𝒆𝒏𝒕𝒊𝒇𝒊𝒆𝒔 𝒑𝒓𝒐𝒈𝒏𝒐𝒔𝒕𝒊𝒄 𝒔𝒖𝒃𝒕𝒚𝒑𝒆𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒕𝒖𝒎𝒐𝒓 𝒎𝒊𝒄𝒓𝒐𝒆𝒏𝒗𝒊𝒓𝒐𝒏𝒎𝒆𝒏𝒕 𝒐𝒇 𝑵𝑺𝑪𝑳𝑪," published in 𝐍𝐚𝐭𝐮𝐫𝐞 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐑𝐞𝐩𝐨𝐫𝐭𝐬, leverages machine learning to enhance our understanding of the tumor microenvironment (TME) in non-small cell lung cancer (NSCLC). This research provides valuable insights that could improve patient management and treatment strategies. 🔸 𝐁𝐚𝐜𝐤𝐠𝐫𝐨𝐮𝐧𝐝 𝐨𝐧 𝐍𝐒𝐂𝐋𝐂: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It is a group of lung cancers that behave similarly, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Understanding the tumor microenvironment in NSCLC is crucial for developing effective treatments and improving patient outcomes. 🔸 𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬: 🔷 𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐏𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐒𝐮𝐛𝐭𝐲𝐩𝐞𝐬: The study utilizes machine learning to identify distinct prognostic subtypes within the tumor microenvironment of NSCLC, providing a deeper understanding of the disease. 🔷 𝐑𝐨𝐥𝐞 𝐨𝐟 𝐌𝐚𝐜𝐡𝐢𝐧𝐞 𝐋𝐞𝐚𝐫𝐧𝐢𝐧𝐠: The integration of advanced machine learning techniques enables the analysis of complex datasets, uncovering patterns and insights that may not be evident through traditional methods. 🔷 𝐓𝐚𝐢𝐥𝐨𝐫𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: By identifying specific subtypes, the research supports the development of more targeted therapies, potentially improving the effectiveness of treatments for patients with NSCLC. 🔸 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲: The findings of this study have important implications for healthcare and pharmacy. A deeper understanding of the tumor microenvironment can lead to the development of more precise treatment strategies, enhancing patient care and outcomes in NSCLC. This research also highlights the potential of machine learning to transform oncology by providing new tools for diagnosis and treatment planning. 🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐩𝐚𝐩𝐞𝐫: https://lnkd.in/gaEWi-vK #PrecisionOncology #MachineLearning #CancerResearch #NSCLC #TumorMicroenvironment #HealthcareInnovation #Pharmacy 🌐 Swenson Pharmacy Advisors (SPA) website: https://lnkd.in/gWFbVAjz

In a recent YouTube clip from the Lex Fridman podcast titled "𝑯𝒐𝒘 𝑵𝒆𝒖𝒓𝒂𝒍𝒊𝒏𝒌 𝒘𝒐𝒓𝒌𝒔," DJ Seo explains the detailed process behind Neuralink's technology, focusing on its three major components: 🔸 𝐓𝐡𝐞 𝐝𝐞𝐯𝐢𝐜𝐞 (𝐍1 𝐢𝐦𝐩𝐥𝐚𝐧𝐭 𝐨𝐫 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤) 🔸 𝐓𝐡𝐞 𝐬𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐫𝐨𝐛𝐨𝐭 🔸 𝐓𝐡𝐞 𝐧𝐞𝐮𝐫𝐚𝐥 𝐬𝐢𝐠𝐧𝐚𝐥 𝐝𝐞𝐜𝐨𝐝𝐢𝐧𝐠 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 The N1 implant involves the insertion of tiny threads into the brain's motor cortex, which record neural signals. These signals are decoded by Neuralink's application, enabling users to control external devices wirelessly. The system is designed to detect and compress neural spikes before transmitting them via Bluetooth to an external device, allowing for real-time interaction and control. DJ Seo highlights the functionality of Neuralink, stating, "𝑾𝒆 𝒘𝒂𝒏𝒕 𝒕𝒐 𝒈𝒆𝒕 𝒕𝒐 𝒂 𝒑𝒐𝒊𝒏𝒕 𝒘𝒉𝒆𝒓𝒆 𝒐𝒏𝒆 𝒄𝒍𝒊𝒄𝒌 𝒂𝒏𝒅 𝒊𝒕 𝒋𝒖𝒔𝒕 𝒅𝒐𝒆𝒔 𝒕𝒉𝒆 𝒔𝒖𝒓𝒈𝒆𝒓𝒚 𝒘𝒊𝒕𝒉𝒊𝒏 𝒎𝒊𝒏𝒖𝒕𝒆𝒔." 🔸 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲: The potential implications for healthcare and pharmacy are noteworthy. Neuralink's ability to interface directly with the brain could improve the management of neurological disorders, offering new approaches for treatment and rehabilitation. In the field of pharmacy, this technology might enable more precise drug delivery systems and personalized treatment plans based on real-time neural feedback, ultimately enhancing patient care and outcomes. 🔗 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬, 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐰𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐜𝐥𝐢𝐩 𝐡𝐞𝐫𝐞: https://lnkd.in/gA8BVQ3X #Neuralink #HealthcareInnovation #BrainInterface #AIHealthcare 🌐 Swenson Pharmacy Advisors (SPA) 𝐖𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/gWFbVAjz

🔷 𝐏𝐚𝐭𝐡𝐰𝐚𝐲𝐬 𝐭𝐨 𝐆𝐨𝐯𝐞𝐫𝐧𝐢𝐧𝐠 𝐀𝐈 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 🔷 Artificial intelligence (AI) has the potential to transform healthcare by enhancing diagnostic accuracy, streamlining operations, and increasing patient engagement. However, alongside the enthusiasm for these technologies, there are significant concerns about patient safety, biases, and data security. Recognizing the need for updated regulatory frameworks, the Stanford Institute for Human-Centered Artificial Intelligence (HAI) convened a closed-door workshop in May 2024. This event brought together 55 leading policymakers, healthcare providers, AI developers, and patient advocates to address key policy gaps in healthcare AI. During the workshop, participants discussed the current challenges in federal healthcare AI policy, focusing on AI software for clinical decision support, enterprise AI tools, and patient-facing AI applications. The discussions highlighted the need for a new regulatory framework to ensure the safe and effective use of AI in healthcare. 🔸𝐊𝐞𝐲 𝐭𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐰𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: 🔹𝐒𝐭𝐫𝐞𝐚𝐦𝐥𝐢𝐧𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥: Proposals for public-private partnerships to manage the evidentiary burden of AI approval and better information sharing during the device clearance process. 🔹𝐇𝐮𝐦𝐚𝐧 𝐎𝐯𝐞𝐫𝐬𝐢𝐠𝐡𝐭 𝐚𝐧𝐝 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲: Balancing the need for human oversight with the efficiency gains from autonomous AI tools, and ensuring transparency in AI tools used in clinical settings. 🔹𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐅𝐚𝐜𝐢𝐧𝐠 𝐀𝐈 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: Clarifying the regulatory status of AI applications to ensure they provide safe and accurate information to patients. These discussions underscore the urgent need for a regulatory framework that can adapt to the rapid development of AI technologies in healthcare. The Stanford HAI Healthcare AI Policy Steering Committee will continue to conduct research and advocate for policies that ensure the safe, equitable, and effective use of AI in healthcare. 🔗 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐰𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐚𝐭: https://lnkd.in/ePM6R8yy #HealthcareAI #AIpolicy #HealthcareInnovation #StanfordHAI 🌐 𝐒𝐰𝐞𝐧𝐬𝐨𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐬 (𝐒𝐏𝐀) 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/gWFbVAjz

Recursion and Exscientia have entered into a definitive agreement to create a global technology-enabled drug discovery leader with comprehensive capabilities. This merger combines Recursion’s biology exploration and translational capabilities with Exscientia’s precision chemistry design and automated synthesis expertise. The goal is to utilize advanced life sciences and technology to deliver treatments more efficiently and at a lower cost compared to traditional methods. The combined business is well-capitalized, with approximately $850 million in cash and cash equivalents, and expects to achieve annual synergies exceeding $100 million. The partnership will also enhance their pipeline, with around 10 clinical readouts anticipated over the next 18 months and potential milestone payments of $200 million over the next two years. 🔸 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲: The implications for healthcare and pharmacy are noteworthy, as this merger aims to streamline the drug discovery and development process. By integrating high-throughput biology and advanced chemistry automation, the new entity seeks to improve the efficiency of developing high-quality medicines. This approach may reduce drug development timelines and costs, ultimately benefiting patients with quicker access to new therapies. The collaboration with leading biopharma companies, such as Roche-Genentech, Sanofi, Bayer, and Merck KGaA, highlights the potential for advancements in oncology, rare diseases, and infectious diseases, positioning the combined company as a significant player in the biotechnology industry. 🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐑𝐞𝐜𝐮𝐫𝐬𝐢𝐨𝐧 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/eTSEfuYv #DrugDiscovery #BiotechInnovation #HealthcareAdvancement 🌐 Swenson Pharmacy Advisors (SPA) 𝐖𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/gWFbVAjz

🌍 𝐍𝐞𝐰 𝐇𝐮𝐦𝐚𝐧 𝐆𝐮𝐭 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐦𝐞 𝐀𝐭𝐥𝐚𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞𝐝! 🌍 A recent study published in Genome Research titled “𝑮𝒍𝒐𝒃𝒂𝒍 𝒄𝒐𝒎𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒏𝒅 𝒇𝒖𝒏𝒄𝒕𝒊𝒐𝒏𝒂𝒍 𝒔𝒕𝒂𝒕𝒆𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒉𝒖𝒎𝒂𝒏 𝒈𝒖𝒕 𝒎𝒊𝒄𝒓𝒐𝒃𝒊𝒐𝒎𝒆 𝒊𝒏 𝒉𝒆𝒂𝒍𝒕𝒉 𝒂𝒏𝒅 𝒅𝒊𝒔𝒆𝒂𝒔𝒆” introduces the most comprehensive Human Gut Microbiome Atlas to date. This freely available resource aims to enhance our understanding of how gut bacteria influence health and disease globally. 🔬 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 🔸 The Atlas covers data from over 6,000 gut microbiome samples across 19 countries, identifying bacterial profiles linked to 23 different diseases. 🔸 By tagging microbiome features to specific diseases, this resource aims to enhance diagnosis and individualized treatment plans for conditions such as colorectal cancer and Crohn’s Disease. 🔸 The study, led by King's College London in collaboration with MetaGenoPolis and the Science for Life Laboratory, is the largest of its kind, setting a new benchmark for microbiome research. 🧬 𝐒𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐜𝐞: Dr. Saeed Shoaie, Senior Lecturer in Systems & Synthetic Biology at King’s College London, emphasized the importance: “The discovery of microbiome patterns common across disease will allow researchers to answer what constitutes a healthy or unhealthy gut microbiome. This will enable healthcare professionals to diagnose diseases with greater clarity and implement effective treatments targeting the microbiome, such as dietary modifications or microbiome transplants.” 🚀 𝐅𝐮𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬: The research team hopes to extend their work to create oral and skin microbiome atlases to address illnesses like eczema and psoriasis. They also aim to trace antimicrobial resistance (AMR) within global populations, a crucial step in combating the projected rise in AMR-related deaths. Dr. Frederick Clasen, co-author and Research Associate at King’s College London, highlighted the initiative: “The threat of AMR requires novel and innovative solutions, and using the microbiome holds great potential for improved diagnosis, surveillance, and treatments. We believe that the Human Gut Microbiome Atlas is an important step toward unlocking the power of microbiome for this purpose.” 🔗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐮𝐝𝐲 𝐡𝐞𝐫𝐞: https://lnkd.in/eesnV2j4 🔗 𝐀𝐜𝐜𝐞𝐬𝐬 𝐓𝐡𝐞 𝐇𝐮𝐦𝐚𝐧 𝐆𝐮𝐭 𝐌𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐦𝐞 𝐀𝐭𝐥𝐚𝐬 (𝐇𝐆𝐌𝐀) 𝐡𝐞𝐫𝐞: https://lnkd.in/gcrNARj #Microbiome #GutHealth #Genomics #Research #Health

💊 𝐈𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 155,000 𝐔𝐒 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐬𝐭𝐬 𝐞𝐦𝐩𝐥𝐨𝐲𝐞𝐝 𝐛𝐲 𝐫𝐞𝐭𝐚𝐢𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐜𝐡𝐚𝐢𝐧𝐬, 𝐚𝐫𝐞 𝐲𝐨𝐮 𝐩𝐫𝐞𝐩𝐚𝐫𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐡𝐞𝐚𝐝𝐰𝐢𝐧𝐝𝐬 𝐟𝐚𝐜𝐢𝐧𝐠 𝐭𝐡𝐢𝐬 𝐬𝐞𝐜𝐭𝐨𝐫 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐧𝐢𝐭𝐞𝐝 𝐒𝐭𝐚𝐭𝐞𝐬? 💊 If the situation in the retail chain pharmacy space continues to deteriorate, do you have the network, skillset, and readiness to compete not only against the more than 13,000 new PharmD graduates but also against the other 155,000 US pharmacists who may also be seeking new opportunities? 𝐍𝐨𝐭 𝐬𝐮𝐫𝐞 𝐰𝐡𝐞𝐫𝐞 𝐭𝐨 𝐬𝐭𝐚𝐫𝐭? 𝐖𝐞 𝐜𝐚𝐧 𝐡𝐞𝐥𝐩. This is all we do, and we do it better than anyone else. 💊 𝐅𝐨𝐫 𝐥𝐞𝐬𝐬 𝐭𝐡𝐚𝐧 𝐨𝐧𝐞 𝐰𝐞𝐞𝐤’𝐬 𝐰𝐚𝐠𝐞𝐬, 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐭𝐚𝐤𝐞 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐬𝐭𝐞𝐩 𝐭𝐨𝐰𝐚𝐫𝐝 𝐚 𝐛𝐫𝐢𝐠𝐡𝐭𝐞𝐫, 𝐦𝐨𝐫𝐞 𝐫𝐞𝐰𝐚𝐫𝐝𝐢𝐧𝐠 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐜𝐚𝐫𝐞𝐞𝐫 💊 At Swenson Pharmacy Advisors (SPA), we specialize in guiding pharmacy professionals like you toward success in non-traditional pharmacy roles. Our 𝐂𝐚𝐫𝐞𝐞𝐫 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭 𝐒𝐮𝐢𝐭𝐞 is designed to equip you with the tools, strategies, and support necessary for success in the dynamic pharmacy and healthcare industries. 𝐖𝐡𝐚𝐭’𝐬 𝐈𝐧𝐜𝐥𝐮𝐝𝐞𝐝: 🔸 𝐂𝐥𝐢𝐟𝐭𝐨𝐧𝐒𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐬 𝟑𝟒 𝐀𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭: Discover your key strengths and align them with your career goals. 🔸 𝐂𝐥𝐢𝐞𝐧𝐭 𝐈𝐧𝐭𝐚𝐤𝐞 𝐅𝐨𝐫𝐦: Share your aspirations so we can tailor our consultation to your unique needs. 🔸 𝟐-𝐇𝐨𝐮𝐫 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐚𝐭𝐢𝐨𝐧: Dive deep into your career goals and opportunities with a focused session. 🔸 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐂𝐚𝐫𝐞𝐞𝐫 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲: Receive a personalized plan with actionable steps and follow-up recommendations. 🔸 𝐄𝐱𝐩𝐞𝐫𝐭 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭: Leverage insights from over 50 specialized advisors. 🔸 𝐁𝐫𝐚𝐧𝐝 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐞 𝐏𝐥𝐮𝐬: Refine your resume, LinkedIn profile, and online presence. 🔸 𝐎𝐧𝐞-𝐇𝐨𝐮𝐫 𝟏:𝟏 𝐃𝐞𝐝𝐢𝐜𝐚𝐭𝐞𝐝 𝐍𝐞𝐭𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐂𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧: Develop a personalized networking strategy with Lee Swenson, PharmD to build meaningful connections and expand your career opportunities. 🔸 𝐓𝐚𝐢𝐥𝐨𝐫𝐞𝐝 𝐂𝐚𝐫𝐞𝐞𝐫 𝐀𝐜𝐭𝐢𝐯𝐚𝐭𝐢𝐨𝐧 𝐑𝐨𝐚𝐝𝐦𝐚𝐩 (𝐓𝐂𝐀𝐑): A comprehensive, personalized 60-page guide to your career success. 🔸 𝐅𝐨𝐥𝐥𝐨𝐰-𝐔𝐩 𝐒𝐮𝐩𝐩𝐨𝐫𝐭: 30-minute follow-up session and exclusive network access. 𝐓𝐚𝐤𝐞 𝐚𝐜𝐭𝐢𝐨𝐧 𝐭𝐨𝐝𝐚𝐲. 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐟𝐮𝐭𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐒𝐏𝐀’𝐬 𝐂𝐚𝐫𝐞𝐞𝐫 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭 𝐒𝐮𝐢𝐭𝐞. 🔗 Learn more about the Career Enhancement Suite at https://lnkd.in/g4p58Gmr #Pharmacy #CareerDevelopment #ProfessionalGrowth ♻️ 𝐑𝐞𝐩𝐨𝐬𝐭 𝐭𝐡𝐢𝐬 𝐢𝐟 𝐲𝐨𝐮 𝐞𝐧𝐣𝐨𝐲𝐞𝐝 𝐢𝐭. 𝐒𝐡𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐚 𝐟𝐫𝐢𝐞𝐧𝐝 𝐰𝐡𝐨'𝐬 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐭𝐨 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐭𝐡𝐞𝐢𝐫 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐜𝐚𝐫𝐞𝐞𝐫! ♻️